ANALYSIS: Medicinal cannabis has been legal since 2016 and while more than one million Australians have been prescribed cannabis products, the industry continues to struggle for profitability.
ANALYSIS: The Supreme Court waved through Mike Smith’s challenge to big emitters, a move likely to discomfort shareholders, directors, and business at large.
ANALYSIS: Kiwis know all about supermarket duopolies, so calls for change in Australia will be closely watched.
ANALYSIS: Could tighter mandatory disclosure rules and a ticking clock on M&A approaches help modernise our market?
ANALYSIS: Paving the way for more affordable, sustainable homes requires pragmatic policy setting and industry frameworks, not the next big shiny thing.
ANALYSIS: Houthi attacks in the Red Sea just the latest in an escalating series of crises causing pain for all the world's exporters.
ANALYSIS: When Kiwis invest in companies on the ASX they are investing alongside superannuation funds, many of which are linked to the union movement. Some people think this is a problem.
Some brickbats and bouquets for whatever it is that happened in 2023.
ANALYSIS: Kiwi company helmed by London-based Texan will be stretching to beat bigger rivals, but has new clarity of purpose.
ANALYSIS: The US requires portfolio managers disclose how personally invested they are in their own funds – it’s time New Zealand did the same.